Mobia Medical (Ticker: MOBI US) is an American commercial-stage medical device company incorporated in Delaware and focused on stroke recovery for survivors with life-altering motor impairments. Its Vivistim Paired Vagus Nerve Stimulation System is described as the first clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments.

Mobia plans to list on NASDAQ on May 8, 2026, following pricing after market close on May 7, 2026. The company is offering 10.0 million primary shares at a price range of $14.00 to $16.00 per share, raising approximately $150 million at the $15.00 midpoint. As the offering is 100% primary shares, IPO proceeds are expected to go to the company. According to the prospectus information provided, Mobia had revenue of approximately $32 million and a net loss of approximately $47 million for the year ended Dec. 31, 2025. Estimated market capitalization is approximately $496 million. Bank of America, J.P. Morgan and Goldman Sachs are acting as bookrunners.